Postmenopausal osteoporosis
Patient preference in the management of postmenopausal osteoporosis with bisphosphonates
... for postmenopausal osteoporosis are the nitrogen-containing bisphosphonates, which are required long term for optimal ...in postmenopausal osteoporosis in clinical trials, but in practice the ...
10
Emerging treatments for postmenopausal osteoporosis – focus on denosumab
... Abstract: The pathway of the receptor activator of the nuclear factor κB ligand (RANKL), RANK and osteoprotegerin (OPG) plays a central role in coupling bone formation and resorp- tion during normal bone turnover and in ...
10
THE CLINICAL AND METABOLIC EFFECTS OF CALCITRIOL IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
... of postmenopausal osteoporosis ...pausal osteoporosis is due to impairment of intesti- nal calcium transport resulting from reduced 1,25(OH) 2 D synthesis associated with impaired ...
6
A SYSTEMATIC REVIEW ON DIAGNOSIS AND MANAGEMENT OF POSTMENOPAUSAL OSTEOPOROSIS
... for postmenopausal osteoporosis in women with low bone mass or with an existing vertebral ...fracture. Osteoporosis is a worldwide health problem related to the aging of the population, and it is ...
11
Strontium Ranelate Using for the Treatment of Postmenopausal Osteoporosis
... The main reason of postmenopausal osteoporosis is high bone turnover due to increased osteoclastic action. Strontium Ranelate is a new drug that is used for the treatment of postmenopausal ...
7
Bisphosphonates Zoledronate and Alendronate for the Management of Postmenopausal Osteoporosis
... with postmenopausal osteoporosis, a randomized controlled extension of the pivotal fracture trial, was conducted to study the long term effect of ZOL by Black et ...
19
Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis
... of osteoporosis and for the treatment of vaginal atrophy in postmenopausal ...In postmenopausal women with low or normal bone mineral density (BMD), lasofoxifene increased BMD at the lumbar spine and ...
11
Medicinal Plants for the Treatment of Postmenopausal Osteoporosis
... Trifoliumpratense , the red clover is a herbaceous type of the flowering plant having a place in the family of Fabaceae , widely seen in Europe , Western Asia and Northwest Africa(Rosso & Pagano, 2005). Red clover ...
16
Safety of Bisphosphonates for Postmenopausal osteoporosis: An Overview of Systematic Reviews
... Overviews of systematic reviews are through summa- rizing evidence from published systematic reviews on a common topic and applied to guide researchers and cli- nicians finding high quality evidence they want. To our ...
11
The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil
... for postmenopausal osteoporosis, densitometry should generally be repeated every 2 ...severe osteoporosis and in patients with a high risk of new fractures, this interval can be reduced, but there ...
9
Profile of teriparatide in the management of postmenopausal osteoporosis
... Abstract: One out of every 2 women within postmenopause are at risk of fracture due to osteoporosis. Fortunately, a growing arsenal of therapies is becoming available to treat this disease and prevent fracture. A ...
8
Efficacy and safety of bazedoxifene for postmenopausal osteoporosis
... postmenopausal osteoporosis without stimulating the endometrium and ...with osteoporosis, further clinical investigations of long-term treatment with this SERM are needed to evaluate the prevention ...
10
Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal
... Abstract: Osteoporosis is a progressive and debilitating disease characterized by a massive bone loss with a deterioration of bone tissues, and a propensity for a fragility ...in postmenopausal ...
6
Bone turnover in postmenopausal osteoporosis Effect of calcitonin treatment
... of postmenopausal osteoporosis in relation to bone turnover, we examined 53 postmenopausal osteoporotic women before and after one year of therapy with salmon calcitonin (sCT), at the dose of 50 IU ...
8
Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
... resorption. Postmenopausal osteoporosis (PMO) is a systemic skeletal disease associated with high levels of RANKL, resulting in a high rate of bone remodeling and an imbalance of bone resorption over bone ...
13
Acute bilateral uveitis and right macular edema induced by a single infusion of zoledronic acid for the treatment of postmenopausal osteoporosis as a substitution for oral alendronate: a case report
... Case presentation: A 63-year-old Asian woman received her first intravenous zoledronic acid treatment for the management of postmenopausal osteoporosis as a more convenient substitute for oral alendronate. ...
5
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
... Abstract: Bisphosphonates are the leading drugs for the treatment of osteoporosis. In randomized controlled trials (RCTs), alendronate, risedronate, and zoledronate have shown to reduce the risk of vertebral, ...
19
QUANTITATION OF CALCIUM METABOLISM IN POSTMENOPAUSAL OSTEOPOROSIS AND IN SCOLIOSIS
... Normal premenopausal woman Normal menopause 10 years ago; asymptomatic gallstones Scoliosis, congenital; idiopathic hypercalciuria Scoliosis, congenital Osteoporosis; hysterectomy 34 yea[r] ...
9
Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
... included a population with a relatively low fracture risk, rather than patients with established osteoporosis, which was modeled more closely in the sensitivity analysis. Therefore, it is likely that our estimates ...
13
Once-monthly risedronate for postmenopausal osteoporosis
... with osteoporosis were randomized to either once-monthly ibandronate 150 mg followed by once-weekly alendronate 70 mg, or the opposite sequence, for a total of 6 ...
10